Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria De Santis

Showing results (191-200 of 278) with videos related to

Pageof 28
Sort By:
Nature Communications|December 13, 2019
Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid cultureGiovanni Giuseppe Giobbe, Claire Crowley, Camilla Luni, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Clinical and Experimental Rheumatology|December 18, 2020
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre studyGiacomo Maria Guidelli, Ombretta Viapiana, Nicoletta Luciano, et al.
Rheumatology (Oxford, England)|May 15, 2024
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre studyGiacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, et al.
The Lancet. Oncology|December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 studyEnrique Grande, José Á Arranz, Maria De Santis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable NeoplasmTorgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Pageof 28

Showing results (191-200 of 278) with videos related to

Sort By:
Pageof 28
Nature Communications|December 13, 2019
Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid cultureGiovanni Giuseppe Giobbe, Claire Crowley, Camilla Luni, et al.
Lancet (London, England)|October 20, 2025
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trialMaria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al.
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Clinical and Experimental Rheumatology|December 18, 2020
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre studyGiacomo Maria Guidelli, Ombretta Viapiana, Nicoletta Luciano, et al.
Rheumatology (Oxford, England)|May 15, 2024
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre studyGiacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, et al.
The Lancet. Oncology|December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 studyEnrique Grande, José Á Arranz, Maria De Santis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable NeoplasmTorgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Pageof 28